Literature DB >> 28864456

History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium.

Albina N Minlikeeva1, Jo L Freudenheim2, Kevin H Eng3, Rikki A Cannioto1, Grace Friel4, J Brian Szender5, Brahm Segal6,7, Kunle Odunsi5,8, Paul Mayor5, Brenda Diergaarde9, Emese Zsiros8, Linda E Kelemen10, Martin Köbel11, Helen Steed12, Anna deFazio, Susan J Jordan13, Peter A Fasching14,15, Matthias W Beckmann15, Harvey A Risch16, Mary Anne Rossing17, Jennifer A Doherty18, Jenny Chang-Claude19,20, Marc T Goodman21, Thilo Dörk22, Robert Edwards23,24, Francesmary Modugno23,24,25, Roberta B Ness26, Keitaro Matsuo27, Mika Mizuno28, Beth Y Karlan29, Ellen L Goode30, Susanne K Kjær31,32, Estrid Høgdall31,33, Joellen M Schildkraut34, Kathryn L Terry35,36, Daniel W Cramer35,36, Elisa V Bandera37, Lisa E Paddock38,39, Lambertus A Kiemeney40, Leon F A G Massuger41, Rebecca Sutphen42, Hoda Anton-Culver43,44, Argyrios Ziogas44, Usha Menon45, Simon A Gayther46,47, Susan J Ramus48,49, Aleksandra Gentry-Maharaj45, Celeste L Pearce50,51, Anna H Wu51, Jolanta Kupryjanczyk52, Allan Jensen31, Penelope M Webb13, Kirsten B Moysich53,2,7.   

Abstract

Background: Comorbidities can affect survival of ovarian cancer patients by influencing treatment efficacy. However, little evidence exists on the association between individual concurrent comorbidities and prognosis in ovarian cancer patients.
Methods: Among patients diagnosed with invasive ovarian carcinoma who participated in 23 studies included in the Ovarian Cancer Association Consortium, we explored associations between histories of endometriosis; asthma; depression; osteoporosis; and autoimmune, gallbladder, kidney, liver, and neurological diseases and overall and progression-free survival. Using Cox proportional hazards regression models adjusted for age at diagnosis, stage of disease, histology, and study site, we estimated pooled HRs and 95% confidence intervals to assess associations between each comorbidity and ovarian cancer outcomes.
Results: None of the comorbidities were associated with ovarian cancer outcome in the overall sample nor in strata defined by histologic subtype, weight status, age at diagnosis, or stage of disease (local/regional vs. advanced).Conclusions: Histories of endometriosis; asthma; depression; osteoporosis; and autoimmune, gallbladder, kidney, liver, or neurologic diseases were not associated with ovarian cancer overall or progression-free survival.Impact: These previously diagnosed chronic diseases do not appear to affect ovarian cancer prognosis. Cancer Epidemiol Biomarkers Prev; 26(9); 1470-3. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2017        PMID: 28864456      PMCID: PMC5649363          DOI: 10.1158/1055-9965.EPI-17-0367

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.090


  8 in total

1.  Effect of autoimmune diseases on risk and survival in female cancers.

Authors:  Kari Hemminki; Xiangdong Liu; Jianguang Ji; Asta Försti; Jan Sundquist; Kristina Sundquist
Journal:  Gynecol Oncol       Date:  2012-07-20       Impact factor: 5.482

2.  The influence of age and co-morbidity on treatment and prognosis of ovarian cancer: a population-based study.

Authors:  H A A M Maas; R F P M Kruitwagen; V E P P Lemmens; S H Goey; M L G Janssen-Heijnen
Journal:  Gynecol Oncol       Date:  2005-04       Impact factor: 5.482

3.  Comorbidity is an independent prognostic factor for the survival of ovarian cancer: a Danish register-based cohort study from a clinical database.

Authors:  Cecilie Sperling; Mette Calundann Noer; Ib Jarle Christensen; Marie Louise Shee Nielsen; Øjvind Lidegaard; Claus Høgdall
Journal:  Gynecol Oncol       Date:  2013-01-03       Impact factor: 5.482

4.  History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium.

Authors:  Albina N Minlikeeva; Jo L Freudenheim; Rikki A Cannioto; J Brian Szender; Kevin H Eng; Francesmary Modugno; Roberta B Ness; Michael J LaMonte; Grace Friel; Brahm H Segal; Kunle Odunsi; Paul Mayor; Emese Zsiros; Barbara Schmalfeldt; Rüdiger Klapdor; Thilo Dӧrk; Peter Hillemanns; Linda E Kelemen; Martin Kӧbel; Helen Steed; Anna de Fazio; Susan J Jordan; Christina M Nagle; Harvey A Risch; Mary Anne Rossing; Jennifer A Doherty; Marc T Goodman; Robert Edwards; Keitaro Matsuo; Mika Mizuno; Beth Y Karlan; Susanne K Kjær; Estrid Høgdall; Allan Jensen; Joellen M Schildkraut; Kathryn L Terry; Daniel W Cramer; Elisa V Bandera; Lisa E Paddock; Lambertus A Kiemeney; Leon F Massuger; Jolanta Kupryjanczyk; Andrew Berchuck; Jenny Chang-Claude; Brenda Diergaarde; Penelope M Webb; Kirsten B Moysich
Journal:  Cancer Causes Control       Date:  2017-03-14       Impact factor: 2.506

5.  Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach.

Authors:  Maryska L G Janssen-Heijnen; Saskia Houterman; Valery E P P Lemmens; Marieke W J Louwman; Huub A A M Maas; Jan Willem W Coebergh
Journal:  Crit Rev Oncol Hematol       Date:  2005-09       Impact factor: 6.312

6.  Survival and prognostic factors in patients with ovarian cancer.

Authors:  Solveig Tingulstad; Finn Egil Skjeldestad; Tore B Halvorsen; Bjørn Hagen
Journal:  Obstet Gynecol       Date:  2003-05       Impact factor: 7.661

7.  Survival of Californian women with epithelial ovarian cancer, 1994-1996: a population-based study.

Authors:  Cynthia D O'Malley; Rosemary D Cress; Sharan L Campleman; Gary S Leiserowitz
Journal:  Gynecol Oncol       Date:  2003-12       Impact factor: 5.482

8.  The impact of comorbidity and stage on ovarian cancer mortality: a nationwide Danish cohort study.

Authors:  Mette S Tetsche; Claus Dethlefsen; Lars Pedersen; Henrik T Sorensen; Mette Norgaard
Journal:  BMC Cancer       Date:  2008-01-29       Impact factor: 4.430

  8 in total
  5 in total

1.  Predictors of Long-Term Survival among High-Grade Serous Ovarian Cancer Patients.

Authors:  Christina L Clarke; Lawrence H Kushi; Jessica Chubak; Pamala A Pawloski; Joanna E Bulkley; Mara M Epstein; Andrea N Burnett-Hartman; Bethan Powell; Celeste L Pearce; Heather Spencer Feigelson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-04-09       Impact factor: 4.254

2.  Risks of female genital tract related cancers (gynecological cancers) or breast cancer in women with and without chronic kidney disease: A population-based cohort study in Taiwan.

Authors:  Wen-Hsun Chang; Huann-Cheng Horng; Chang-Ching Yeh; Chao-Yu Guo; Yiing-Jeng Chou; Nicole Huang; Hsin-Yi Huang; Yi-Jen Chen; Wen-Ling Lee; Peng-Hui Wang
Journal:  Medicine (Baltimore)       Date:  2018-03       Impact factor: 1.889

3.  Cancer Loyalty Card Study (CLOCS): protocol for an observational case-control study focusing on the patient interval in ovarian cancer diagnosis.

Authors:  Hannah R Brewer; Yasemin Hirst; Sudha Sundar; Marc Chadeau-Hyam; James M Flanagan
Journal:  BMJ Open       Date:  2020-09-08       Impact factor: 2.692

Review 4.  Endometriosis and endometriosis-associated cancers: new insights into the molecular mechanisms of ovarian cancer development.

Authors:  Amy Dawson; Marta Llauradó Fernandez; Michael Anglesio; Paul J Yong; Mark S Carey
Journal:  Ecancermedicalscience       Date:  2018-01-25

5.  Endometriosis is the independent prognostic factor for survival in Chinese patients with epithelial ovarian carcinoma.

Authors:  Tong Ren; Shu Wang; Jian Sun; Ji-Min Qu; Yang Xiang; Keng Shen; Jing He Lang
Journal:  J Ovarian Res       Date:  2017-10-03       Impact factor: 4.234

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.